Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CMD001
MIFTS: 41

Comedo Carcinoma

Categories: Cancer diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications
Sources

Aliases & Classifications for Comedo Carcinoma

About this section

MalaCards integrated aliases for Comedo Carcinoma:

Name: Comedo Carcinoma 11 14 75
Comedocarcinoma 11 71 75
High Grade Ductal Breast Carcinoma in Situ 71

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:5670
NCIt 49 C4188
SNOMED-CT 68 36425007
UMLS 71 C0334370 C1334002
Sources

Summaries for Comedo Carcinoma

About this section

Disease Ontology: 11 A ductal carcinoma in situ that is characterized by the presence of comedo-type of tumor cell necrosis in which the necrotic areas are surrounded by a solid proliferation of malignant pleomorphic cells.

MalaCards based summary: Comedo Carcinoma, also known as comedocarcinoma, is related to lobular neoplasia and ductal carcinoma in situ. An important gene associated with Comedo Carcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are COPI-independent Golgi-to-ER retrograde traffic and Breast cancer pathway. Affiliated tissues include breast, prostate and lymph node, and related phenotypes are neoplasm and normal

Wikipedia: 75 Comedocarcinoma is a kind of breast cancer that demonstrates comedonecrosis, which is the central... more...
Sources

Related Diseases for Comedo Carcinoma

About this section

Diseases related to Comedo Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 305)
# Related Disease Score Top Affiliating Genes
1 lobular neoplasia 29.0 TP53 PGR KRT5 ESR1 ERBB2 BRCA2
2 ductal carcinoma in situ 28.3 TP53 PGR KRT5 KRT14 ESR1 ERBB2
3 prostate cancer 28.2 TP53 PTGER4 PGR KRT5 ESR1 ERBB2
4 scirrhous adenocarcinoma 10.3 PGR ERBB2
5 her2-receptor negative breast cancer 10.3 PGR ERBB2
6 breast abscess 10.3 PGR ERBB2
7 uterine corpus adenosarcoma 10.3 PGR ESR1
8 adult cystic nephroma 10.3 PGR ESR1
9 vagina leiomyosarcoma 10.3 PGR ESR1
10 vulvar benign neoplasm 10.3 PGR ESR1
11 triple-receptor negative breast cancer 10.3 PGR ERBB2
12 diffuse peritoneal leiomyomatosis 10.3 PGR ESR1
13 peritoneal benign neoplasm 10.3 PGR ESR1
14 progesterone resistance 10.3 PGR ESR1
15 linitis plastica 10.3 PGR ERBB2
16 intravenous leiomyomatosis 10.3 PGR ESR1
17 vulvar syringoma 10.3 PGR ESR1
18 apocrine adenosis of breast 10.3 TP53 ERBB2
19 liver leiomyoma 10.3 PGR ESR1
20 ovarian seromucinous carcinoma 10.3 PGR ESR1
21 pregnancy adenoma 10.3 PGR KRT5
22 parotid gland cancer 10.3 TP53 ERBB2
23 acanthoma 10.3 TP53 KRT5
24 adult type testicular granulosa cell tumor 10.3 PGR KRT5
25 cervical polyp 10.3 PGR ESR1
26 eccrine papillary adenocarcinoma 10.3 PGR KRT5
27 laryngeal mucoepidermoid carcinoma 10.3 KRT14 ERBB2
28 gestational ovarian choriocarcinoma 10.3 TP53 ERBB2
29 prostate stromal sarcoma 10.2 PGR ESR1
30 vulvar leiomyoma 10.2 PGR ESR1
31 external ear carcinoma 10.2 PGR KRT5
32 mucoepidermoid esophageal carcinoma 10.2 TP53 KRT5
33 granulomatous endometritis 10.2 PGR ESR1
34 vagina sarcoma 10.2 PGR ESR1
35 breast adenomyoepithelioma 10.2 KRT5 KRT14
36 myoepithelial carcinoma 10.2 KRT5 KRT14
37 breast adenoma 10.2 PGR KRT5
38 localized osteosarcoma 10.2 TP53 ERBB2
39 breast leiomyosarcoma 10.2 KRT5 ESR1
40 necrotizing sialometaplasia 10.2 TP53 KRT5
41 autosomal dominant generalized epidermolysis bullosa simplex, severe form 10.2 KRT5 KRT14
42 ovarian serous cystadenofibroma 10.2 TP53 PGR
43 ovarian serous adenofibroma 10.2 TP53 PGR
44 adhesions of uterus 10.2 PGR ESR1
45 epidermolysis bullosa simplex 1b, generalized intermediate 10.2 KRT5 KRT14
46 estrogen excess 10.2 PGR ESR1
47 epidermolysis bullosa simplex 1d, generalized, intermediate or severe, autosomal recessive 10.2 KRT5 KRT14
48 adenoid squamous cell carcinoma 10.2 TP53 KRT5
49 gastroesophageal junction adenocarcinoma 10.2 TP53 ERBB2
50 proliferative type fibrocystic change of breast 10.2 KRT5 KRT14

Graphical network of the top 20 diseases related to Comedo Carcinoma:



Diseases related to Comedo Carcinoma
Sources

Symptoms & Phenotypes for Comedo Carcinoma

About this section

MGI Mouse Phenotypes related to Comedo Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.03 AR BRCA2 ERBB2 ESR1 KRT14 PGR
2 normal MP:0002873 10.01 AR BRCA2 ERBB2 ESR1 GP5 PGR
3 limbs/digits/tail MP:0005371 9.87 AR BRCA2 ERBB2 ESR1 KRT5 PGR
4 muscle MP:0005369 9.85 AR ERBB2 ESR1 PGR PTGER4 TP53
5 behavior/neurological MP:0005386 9.81 AR BRCA2 ERBB2 ESR1 KRT5 LXN
6 digestive/alimentary MP:0005381 9.8 AR BRCA2 ERBB2 ESR1 KRT14 KRT5
7 mortality/aging MP:0010768 9.65 AR BRCA2 ERBB2 ESR1 KRT14 KRT5
8 integument MP:0010771 9.32 AR BRCA2 ERBB2 ESR1 KRT14 KRT5
Sources

Drugs & Therapeutics for Comedo Carcinoma

About this section

Search Clinical Trials, NIH Clinical Center for Comedo Carcinoma

Sources

Genetic Tests for Comedo Carcinoma

About this section
Sources

Anatomical Context for Comedo Carcinoma

About this section

Organs/tissues related to Comedo Carcinoma:

MalaCards : Breast, Prostate, Lymph Node, Bone
Sources

Publications for Comedo Carcinoma

About this section

Articles related to Comedo Carcinoma:

(show top 50) (show all 136)
# Title Authors PMID Year
1
Impact of Histological Subtype on Survival in Canine Mammary Carcinomas: a Retrospective Analysis of 155 Cases. 62
34340801 2021
2
Prognostic significance of morphological patterns of Gleason grade 5 prostatic adenocarcinoma diagnosed on needle biopsy. 62
33386122 2021
3
Pure Ductal Carcinoma in Situ in The Male Breast: A Rare Entity. 62
31912019 2020
4
Histopathological Prognostic Factors for Colic Adenocarcinoma. 62
30746162 2018
5
Comparative histopathology and immunohistochemistry of human and canine mammary tumors. 62
30105215 2018
6
Prognostic Significance of Canine Mammary Tumor Histologic Subtypes: An Observational Cohort Study of 229 Cases. 62
28355108 2017
7
Histopathological Study on Conservatively Operated Breast Carcinomas. 62
30581581 2016
8
Diagnosis of Gleason pattern 5 prostate adenocarcinoma on core needle biopsy: an interobserver reproducibility study among urologic pathologists. 62
25929349 2015
9
Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. 62
26111977 2015
10
Diagnostic evaluation of ductal carcinoma in situ of the breast: ultrasonographic, mammographic and histopathologic correlations. 62
25479813 2015
11
Adenocarcinoma of the prostate with Gleason pattern 5 on core biopsy: frequency of diagnosis, morphologic subpatterns, and relation to pattern distribution based on the modified Gleason grading system. 62
25228336 2014
12
Immunohistochemical vascular factor expression in canine inflammatory mammary carcinoma. 62
24048323 2014
13
Mitochondrial D-loop mutations and polymorphisms are connected with canine malignant cancers. 62
23656294 2014
14
Analysis of a new histological and molecular-based classification of canine mammary neoplasia. 62
24003019 2014
15
Local recurrence after ductal carcinoma in situ breast conserving treatment. Analysis of 195 cases. 62
23538041 2013
16
Our orientation regarding the ductal carcinoma in situ of the breast. 62
23110914 2012
17
Ultrasonographic detection and characterization of asymptomatic ductal carcinoma in situ with histopathologic correlation. 62
21498298 2011
18
Predictors of local recurrence in a population-based cohort of women with ductal carcinoma in situ treated with breast conserving surgery alone. 62
20645008 2011
19
Ductal carcinoma in situ of the breast in younger women: a subgroup of patients at high risk. 62
20889280 2010
20
Expression of E-Cadherin in breast carcinomas and its association with other biological markers - a prospective study. 62
22930617 2010
21
Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX. 62
19291713 2009
22
Ductal carcinoma in situ of the breast: our experience. 62
19351465 2009
23
[Ductal carcinoma in situ of the breast (DCIS) under 40: a specific management?]. 62
18467151 2008
24
In situ and invasive components of mammary adenocarcinoma: comparison of Her-2/neu status. 62
17879632 2007
25
[Salivary duct carcinoma of the sublingual gland--a case report]. 62
16586279 2006
26
Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. 62
16702375 2006
27
Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast. 62
16324200 2005
28
Histopathological review of sebaceous carcinoma of the eyelid. 62
16008694 2005
29
Mammography of ductal carcinoma in situ of the breast: review of 909 cases with radiographic-pathologic correlations. 62
15797293 2005
30
Intraductal papilloma with "comedo-like" necrosis, a diagnostic pitfall. 62
15494933 2004
31
Prognostic value of morphology and hormone receptor status in breast cancer - a population-based study. 62
15365566 2004
32
Vulvar Paget's disease with underlying adenocarcinoma simulating breast carcinoma: case report and review of the literature. 62
15361217 2004
33
Management of bilateral breast carcinoma: long-term results. 62
15521255 2004
34
[Ductal carcinoma in situ of the breast. Analysis of 882 cases]. 62
15026697 2004
35
Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. 62
14557212 2003
36
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. 62
12874759 2003
37
Surface topography and ultrastructure correlation between human breast infiltrating ductal carcinoma of non special type and coexisting human breast infiltrating ductal carcinoma of non special type with in situ comedo carcinoma. 62
17472243 2003
38
Surgical management of ductal carcinoma in situ in Australia in 1995. 62
12534380 2002
39
Extramammary Paget Disease of the Axilla Associated With Comedo-like Apocrine Carcinoma In Situ. 62
12142618 2002
40
Detection method and breast carcinoma histology. 62
12209738 2002
41
Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. 62
12101106 2002
42
Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. 62
12095552 2002
43
Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. 62
11668470 2001
44
Ultrastructure of the periductal area of comedo carcinoma in situ of the breast. 62
11508833 2001
45
Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. 62
11418009 2001
46
An in vitro model of human breast carcinogenesis: epigenetic aspects. 62
11261834 2001
47
[Evaluation of prognostic factors in breast cancer EC I-II and the importance of local recurrence]. 62
16161722 2001
48
Cytopathology of metastatic breast cancer. 62
11899649 2000
49
External beam irradiation plus (192)Ir implant after breast-preserving surgery in women with early breast cancer. 62
11020573 2000
50
Sentinel node biopsy in ductal carcinoma in situ patients. 62
10674443 2000
Sources

Variations for Comedo Carcinoma

About this section

Cosmic variations for Comedo Carcinoma:

8 (show top 50) (show all 369)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149317650 ZFHX3 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2403A>T p.K801N 16:72957743-72957743 7
2 COSM87291166 ZFHX3 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2403A>T p.K801N 16:72957743-72957743 7
3 COSM102041732 ZFHX3 breast,NS,carcinoma in situ,ductal carcinoma in situ c.-23-6778A>T p.? 16:72957743-72957743 7
4 COSM143944147 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.265C>T p.R89W 17:7674221-7674221 7
5 COSM112254852 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 17:7674947-7674947 7
6 COSM122733862 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.422G>A p.R141H 17:7673802-7673802 7
7 COSM144092525 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.110G>C p.R37P 17:7674944-7674944 7
8 COSM112253807 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 17:7674230-7674230 7
9 COSM143157019 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.265C>T p.R89W 17:7674221-7674221 7
10 COSM111766786 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.587G>C p.R196P 17:7674944-7674944 7
11 COSM144652630 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.467T>C p.I156T 17:7674947-7674947 7
12 COSM144650760 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.701G>A p.R234H 17:7673802-7673802 7
13 COSM121875541 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.422G>A p.R141H 17:7673802-7673802 7
14 COSM144092363 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.359G>A p.G120E 17:7673784-7673784 7
15 COSM142837551 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 7
16 COSM122734399 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.346C>T p.R116W 17:7674221-7674221 7
17 COSM87900157 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>T p.R273L 17:7673802-7673802 7
18 COSM105621872 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 17:7674947-7674947 7
19 COSM106053434 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 7
20 COSM144015040 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.785G>T p.R262L 17:7673802-7673802 7
21 COSM93185256 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>T p.R273L 17:7673802-7673802 7
22 COSM93190437 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.517G>T p.V173L 17:7675095-7675095 7
23 COSM145017944 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.625C>T p.R209W 17:7674221-7674221 7
24 COSM111758868 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 7
25 COSM142837352 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.743G>A p.R248Q 17:7674220-7674220 7
26 COSM144087106 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.266G>A p.R89Q 17:7674220-7674220 7
27 COSM145018679 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.707G>T p.C236F 17:7673796-7673796 7
28 COSM121876459 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.346C>T p.R116W 17:7674221-7674221 7
29 COSM93191567 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.587G>C p.R196P 17:7674944-7674944 7
30 COSM144048390 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.678G>C p.M226I 17:7674252-7674252 7
31 COSM142837497 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 17:7674230-7674230 7
32 COSM144651436 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.625C>T p.R209W 17:7674221-7674221 7
33 COSM105667399 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 17:7674252-7674252 7
34 COSM144013367 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.710G>A p.R237Q 17:7674220-7674220 7
35 COSM144026584 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.499C>G p.H167D 17:7675080-7675080 7
36 COSM112253879 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 7
37 COSM143378524 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.719G>A p.G240E 17:7673784-7673784 7
38 COSM111759630 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.797G>A p.G266E 17:7673823-7673823 7
39 COSM142560553 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.625C>T p.R209W 17:7674221-7674221 7
40 COSM143945376 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.341G>T p.R114L 17:7673802-7673802 7
41 COSM142866376 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 17:7674252-7674252 7
42 COSM93183281 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>A p.R273H 17:7673802-7673802 7
43 COSM143156843 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.266G>A p.R89Q 17:7674220-7674220 7
44 COSM111797204 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 17:7674252-7674252 7
45 COSM87898709 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 7
46 COSM105620276 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.743G>A p.R248Q 17:7674220-7674220 7
47 COSM122748281 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.136C>G p.H46D 17:7675080-7675080 7
48 COSM106067001 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.532C>G p.H178D 17:7675080-7675080 7
49 COSM145024750 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.400G>T p.V134L 17:7675095-7675095 7
50 COSM144014340 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.791G>T p.C264F 17:7673796-7673796 7
Sources

Expression for Comedo Carcinoma

About this section
Search GEO for disease gene expression data for Comedo Carcinoma.
Sources

Pathways for Comedo Carcinoma

About this section

Pathways related to Comedo Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
COPI-independent Golgi-to-ER retrograde traffic 66
Show member pathways
 12.22 PGR KRT5 KRT14 AR
2
Breast cancer pathway 74
Show member pathways
 11.79 TP53 PGR ESR1 ERBB2 BRCA2
3
Signaling by ERBB4 66
Show member pathways
 11.78 PGR ESR1 ERBB2
4
Integrated breast cancer pathway 74
11.74 TP53 ESR1 BRCA2 AR
5
Nuclear receptors 74
Show member pathways
 11.71 PGR ESR1 AR
6
Glucocorticoid receptor regulatory network 61
11.47 TP53 KRT5 KRT14
7
Validated nuclear estrogen receptor alpha network 61
11.36 PGR LCOR ESR1
8
Validated transcriptional targets of deltaNp63 isoforms 61
11.17 KRT5 KRT14 BRCA2
9
Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) 74
10.84 PGR ESR1 ERBB2
10
Cellular roles of Anthrax toxin 61
10.77 PGR ESR1
11
Mammary gland development pathway - Puberty (Stage 2 of 4) 74
9.91 PGR ESR1 ERBB2
Sources

GO Terms for Comedo Carcinoma

About this section

Biological processes related to Comedo Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.62 TP53 BRCA2
2 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.46 TP53 ESR1
3 negative regulation of miRNA maturation GO:1903799 9.43 TP53 ESR1
4 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.26 PGR AR
5 intracellular steroid hormone receptor signaling pathway GO:0030518 9.1 PGR ESR1 AR

Molecular functions related to Comedo Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase binding GO:0051117 9.73 PGR ESR1 AR
2 nuclear receptor activity GO:0004879 9.63 PGR ESR1 AR
3 transcription coactivator binding GO:0001223 9.43 PGR ESR1 AR
4 steroid binding GO:0005496 9.1 PGR ESR1 AR
Sources

Sources for Comedo Carcinoma

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....